Journal
PHARMACEUTICALS
Volume 14, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ph14101057
Keywords
epilepsy; neurodegenerative diseases; Alzheimer's disease; Parkinson's disease; Huntington's disease; multiple sclerosis
Categories
Funding
- Spanish Ministry of Science, Innovation and Universities [FJC2018-036012-I]
- Instituto de Salud Carlos III (ISCIII) Accion Estrategica en Salud, integrated into the Spanish National R+D+I Plan
- ISCIII Subdireccion General de Evaluacion
- Fondo Europeo de Desarrollo Regional (FEDER Una manera de hacer Europa) [PI17/01474, PI19/00335]
- European Social Fund (ESFInvesting in your future) [CD19/00232]
- Spanish Ministry of Economy and Competitiveness [SAF2017-84283-R]
- CIBERNED [CB06/05/0024]
- Portuguese Science and Technology Foundation (FCT) [UIDB/04469/2020]
- CIBERNED (Instituto de Salud Carlos III (ISCIII))
- EU/EFPIAInnovative Medicines Initiative Joint Undertaking from EXIT project [115975]
- EUEuronanomed3 Program JCT2017 from PREADAPT project [AC17/00100]
- Joint Program for Neurodegenerative Diseases (JPND) [AC19/00097, PI13/02434, PI16/01861, BA19/00020, PI19/01301]
- Instituto de Salud Carlos III (ISCIII)- Subdireccion Generalde Evaluacion
- Fondo Europeo de Desarrollo Regional (FEDERUna manera de HacerEuropa)
- Fundacion bancaria La Caixa
- Grifols SA (GR@ACE project
Ask authors/readers for more resources
Epilepsy is a chronic disease of the central nervous system characterized by an electrical imbalance in neurons. The molecular processes that trigger epileptic seizures and promote neurotoxic effects are currently focused on the glutamate pathway and influx of calcium ions into neurons. Common molecular links between epilepsy and other neurodegenerative diseases have led to investigation of antiseizure drugs for therapeutic potential in these pathologies.
Epilepsy is a chronic disease of the central nervous system characterized by an electrical imbalance in neurons. It is the second most prevalent neurological disease, with 50 million people affected around the world, and 30% of all epilepsies do not respond to available treatments. Currently, the main hypothesis about the molecular processes that trigger epileptic seizures and promote the neurotoxic effects that lead to cell death focuses on the exacerbation of the glutamate pathway and the massive influx of Ca2+ into neurons by different factors. However, other mechanisms have been proposed, and most of them have also been described in other neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, or multiple sclerosis. Interestingly, and mainly because of these common molecular links and the lack of effective treatments for these diseases, some antiseizure drugs have been investigated to evaluate their therapeutic potential in these pathologies. Therefore, in this review, we thoroughly investigate the common molecular pathways between epilepsy and the major neurodegenerative diseases, examine the incidence of epilepsy in these populations, and explore the use of current and innovative antiseizure drugs in the treatment of refractory epilepsy and other neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available